Emerging drugs for treatment of urinary incontinence

Bibliography

• Abrams P, Cardozo L, Fall M, The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21(2):167-78
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997;104:1374-79
   PubMedGoogle Scholar
• Getliffe K, Dolman M. Normal and abnormal bladder function. In: Getliffe K, Dolman M, editors, Promoting continence. A clinical and research resource. 2nd edition. Baillière Tindall, London; 2007
   Google Scholar
• Abrams P, Cardozo L, Khoury S, 4th edition. Health Publications Ltd; 2009
   Google Scholar
• McGrowther CW, Shaw C, Perry SI, Epidemiology (Europe). In: Cardozo L, Staskin D, editors, Textbook of female urology and urogynaecology. Isis Medical Media, Oxford; 2001. p. 21-35
   Google Scholar
• Colley W. Five essential interventions in urinary incontinence care. Continence Essentials 2008;1:40-3
   Google Scholar
• Andersson K-E, Wein AJ. Pharmacology of the lower urinary tract- Basis for current and future treatments of Urinary incontinence. Pharmacol Rev 2004;56(4):581
   PubMed Web of Science ®Google Scholar
• Wein AJ. Pathophysiology and categorisation of voiding dysfunction. In: Walsh P, Retik A, Vaughan ED Jr, Wein AJ, editors, Campbells urology. 8th edition. Saunders, Philadelphia; 2002. p. 887-898
   Google Scholar
• Andersson KE. LUTS treatment: future treatment options. Neurourol Urodyn 2007;26(6 Suppl):934-47
   PubMed Web of Science ®Google Scholar
• NICE Guideline 40. The Management of Urinary Incontinence in Women. Department of Health. Available from: www.nice.org.uk. 2006
   Google Scholar
• Hashim H, Abrams P. Do symptoms of overactive bladder predict urodynamics detrusor overactivity? Neurourol Urodyn 2004;23(5/6):484
   Web of Science ®Google Scholar
• Nilvebrant L, Anderson K-E, Gillberg PG. Tolterodine-a new bladder selective anti muscarinics agent. Eur J Pharmacol 1997b;134:418
   Google Scholar
• Van Kerrebroeck P, Kreder K, Jonus U, Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001;57(3):41416
   Google Scholar
• Diokno AC, Appell RA, Sand PK, Prospective , randomised, double-blind study of the efficacy and tolerability of the extended release formulations of Oxybutinin and tolterodine for overactive bladder: results of OPERA trial. Mayo Clin Proc 2003;78(6):687
   PubMed Web of Science ®Google Scholar
• Chapple CR, Martinez-Garcia R, Selvaggi L, A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder: results of the STAR trial. Eur Urol 2005;48(3):464
   PubMed Web of Science ®Google Scholar
• Chapple CR, Fianu-Jonsson A, Indig M, STAR study group. Treatment outcomes in the STAR study: a sub analysis of Solifenacin 5 mg and tolterodine ER 4mg. Eur Urol 2007;52(4):1195
   PubMed Web of Science ®Google Scholar
• Cardozo L, Hebetadörfer E, Milani R, Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double blind, placebo-controlled, rising-dose trial. BJU Int 2008;102(9):1120-7
   PubMed Web of Science ®Google Scholar
• Michel MC, Wetterauer U, Vogel M, Cardiovascular safety and overall tolerability of Solifenacin in routine clinical use: a 12 week, open-label, post-marketing surveillance study. Drug Saf 2008;31(6):505
   PubMed Web of Science ®Google Scholar
• Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well tolerated once daily treatment for overactive bladder. Eur Urol 2004;45(4):420
   PubMed Web of Science ®Google Scholar
• Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008;62(11):1792-800
   PubMed Web of Science ®Google Scholar
• Chapple C, Van Kerrebroeck P, Tubaro A, Millard R. Fesoterodine in non-neurogenic voiding dysfunction-results on efficacy and safety in a phase III trial. Eur Urol Suppl 2006;5(2):117
   Web of Science ®Google Scholar
• Herschorn S, Swift S, Guan Z, Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head to head placebo controlled trial. BJU Int 2010;105(1):58-66
   PubMed Web of Science ®Google Scholar
• Schladitz-Keil G, Spahn H, Mutschler E. Determination of bioavailability of the quaternary ammonium compound trospium chloride in man from urinary excretion data. Arzneimittelforschung Drug Res 1986;36:984-7
   Google Scholar
• Fusgen I, Hauri D. Trospium chloride: an effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther 2000;38(5):223-3
   PubMed Web of Science ®Google Scholar
• Staskin DR, Rosenberg MT, Sand PK, A Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract 2009;63(12):1715-23
   PubMed Web of Science ®Google Scholar
• Frohlich G, Burmeister S, Wiedemann A, Intravesical instillation of trospium chloride, Oxybutynin and verapamil for relaxation of bladder detrusor muscle. A Placebo controlled, randomised clinical test. Arzneimitteelforschung 1998;48(5):486
   PubMed Web of Science ®Google Scholar
• Hughes KM, Lang JCT, Lazare R, Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992;22:859-69
   PubMed Web of Science ®Google Scholar
• Baigrie RJ, Kelleher JP, Fawcett DP, Pengelly AW. Oxybutynin: is it safe? Br J Urol 1988;62:319-22
   PubMedGoogle Scholar
• Anderson RU, Mobley D, Blank B, Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999;161(6):1809-12
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR, Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62(2):237-42
   PubMed Web of Science ®Google Scholar
• Staskin DR, Dmochowski RR, Sand PK, Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol 2009;181:1764-72
   Google Scholar
• Lee KS, Lee HW, Choo MS, Urinary urgency outcomes after propaverine treatment for an overactive bladder. BJU Int 2009. [Epub ahead of print]
   Google Scholar
• Baldessarini KJ. Drugs in the treatment of psychiatric disorders. In: Gilman, , editors, The pharmacological basis of therapeutics. 7th edition. McMillan Publishing Co. 1985. p. 387-445
   Google Scholar
• Castleden CM, Duffin HM, Gulati RS. Double-blind study of imipramine and placebo for incontinence due to bladder instability. Age Aging 1986;15:299-303
   PubMed Web of Science ®Google Scholar
• Diokno AC, Hyndman CW, Hardy DA, Lapides J. Comparison of action of imipramine (Tofranil) and propantheline (Probanthine) on detrusor contraction. J Urol 1972;107:42-3
   PubMed Web of Science ®Google Scholar
• Robinson D, Cardozo L, Terpstra G, Bolodeoku J. A randomised double blind placebo controlled study to evaluate the efficacy of tamsulosin OCAS in the management of women with overactive bladder. BJU Int 2007;100(4):840-5
   Google Scholar
• Schurch B, Stohrer M, Kramer G, Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692-7
   PubMed Web of Science ®Google Scholar
• Sahai A, Khan MS, Dasgupta P. Efficacy of Botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single centre, randomised ,double-blind, placebo controlled trial. J Urol 2007;177(6):2231
   PubMed Web of Science ®Google Scholar
• Brubaker L, Ritcher HE, Visco AG, Pelvic floor disorders network, refractory idiopathic urge incontinence and botulinum A injection. J Urol 2008;180(1):217
   PubMed Web of Science ®Google Scholar
• Karsenty G, Denys P, Ameranco G, Botulinum toxin a intradetrusor injections in adults with neurogenic Detrusor overactivity: a systemic literature review. Eur Urol 2008;53(2):275
   PubMed Web of Science ®Google Scholar
• Eichel R, Lang C Alloussi S, Botulinum toxin a (dysport®), a safe modern treatment regime in the therapy of drug refractorical detrusor overactivity, 5 years of clinical experience. European Urology Supplements 2008;7(3):213-213
   Web of Science ®Google Scholar
• Fowler CJ, Jewkes D, McDonald WI, Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 1992;339:1
   PubMedGoogle Scholar
• Kim DY, Chancellor MB. Intravesical neuromodulatory drugs: capsaicin and Resiniferatoxin to treat the overactive bladder. J Endourol 2000;14:97-103
   PubMed Web of Science ®Google Scholar
• Hendrix SL, Cochrane BB, Nygard IE, Effects of oestrogen with and without progestin on urinary incontinence. JAMA 2005;293(8):935
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lose G, McClish D, A systemic review of the effects of oestrogen for symptoms of overactive bladder. Acta Obstetr Gynaecol Scand 2004;83:892
   PubMed Web of Science ®Google Scholar
• Cody JD, Richardson K, Moehrer B, Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Databse Syst Rev 2009;(4):CD001405
   Google Scholar
• Robinson D, Cardozo L, Akeson M, Antidiuresis: a new concept in managing female daytime urinary incontinence. BJU Int 2004;93:996-1000
   PubMed Web of Science ®Google Scholar
• Hashim H, Malmberg L, Graugaard-Jenson C, Abrams P. Desmopressin, as a “designer drug” in the treatment of overactive bladder syndrome. Neuro Urol 2009;28:40-6
   PubMed Web of Science ®Google Scholar
• Laval KU, Lutzeyer W. Spontaneous phasic activity of the detrusor: a cause of uninhibited contractions in unstable bladder. Urol Int 1980;35:182-7
   PubMed Web of Science ®Google Scholar
• Shieh C-C, Brune ME, Buckner SA, Characterisation of a novel ATP-sensitive K+ channel opener, A-251179, on urinary bladder relaxation and cystometric parameters. Br J Pharmacol 2007;151:467
   PubMed Web of Science ®Google Scholar
• Sassani P, Sherif R. Aboseif. Curr Urol Rep 2009;10:333-7
   PubMedGoogle Scholar
• Andersson KE. Current concepts in the treatment of disorders of micturition. Drugs 1988;35:477
   PubMed Web of Science ®Google Scholar
• Katofiasc MA, Nissen J, Audia JE, Comparison of the effects of serotonin selective, and dual serotonin and nor epinephrine selective, and dual serotonin and nor epinephrine reuptake inhibitors on lower urinary tract functions in cats. Life Sci 2002;71(11):1227
   PubMed Web of Science ®Google Scholar
• Mariappan P, Ballantyne Z, N'Dow JMO, Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress incontinence. Cochrane Database Syst Rev 2005;(3):CD004742
   Google Scholar
• Hashim H, Abrams P. Pharmacologic management of women with mixed urinary incontinence. Drugs 2006;66(5):591
   PubMed Web of Science ®Google Scholar
• Mattisson A, Abrams P, Van Kerrebroek P, Efficacy of Desmopressin in the treatment of nocturia: a double blind placebo controlled study in men. Br J Urol Int 2002;89(9):855-62
   Google Scholar
• Henry J, editor, the British Medical Association New Guide to Medicines and Drugs, Dorling Kindersley, London; 1998
   Google Scholar
• Schroder A, Colli E, Maggi M, Andersson KE. Effects of a vitamin D3 analogue in a rat model of bladder outflow obstruction. BJU Int 2006;98:637-42
   PubMed Web of Science ®Google Scholar
• Peters SL, Schmidt M, Michel MC. Rho Kinase: a target for treating urinary bladder dysfunction? Trends Pharmacol Sci 2006;27(9):492
   PubMed Web of Science ®Google Scholar
• Colli E, Digesu GA, Oliveri L. Overactive bladder treatments in early phase clinical trials. Expert Opin Investig Drugs 2007;16(7):999-1007
   PubMed Web of Science ®Google Scholar
• Tiwari A. Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility. I Drugs 2009;12(6):381-93
   PubMed Web of Science ®Google Scholar
• Otsuka A, Shinbo H, Matsumoto R, Expression and functional role of beta adrenoreceptors in the human bladder urothelium. Naunyn Schemiedebergs Arch Pharmacol 2008;377:473-81
   PubMed Web of Science ®Google Scholar
• Kadioh KP, Igawa Y, Takeda H, Effects of selective beta2 and beta3–adrenoreceptor agonists on detrusor hyperreflexia in conscious cerebral infracted rats. J Urol 2002;168(3):1247
   PubMed Web of Science ®Google Scholar
• Chapple CR, Yamaguchi O, Ridder A, Clinical proof of concept study (Blossom) shows novel beta3 adrenoreceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder [abstract 674]. Eur Urol Suppl 2008;7(3):239
   Web of Science ®Google Scholar
• Ishizuka O, Mattiasson A, Andersson KE. Effects of neurokinin receptor antagonists on L-dopa induced bladder hyperactivity in normal conscious rats. J Urol 1995;154:1548-51
   PubMed Web of Science ®Google Scholar
• Seiki S, Erickson KA, Seiki M, Elimination of rat spinal neurons expressing neurokinin 1 receptors reduces bladder overactivity and spinal c-fos expression induced by bladder irritation. Am J Physiol Renal Physiol 2005;288:F466-73
   PubMed Web of Science ®Google Scholar
• Green SA, Alon A, Ianus J, Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 2006;176(6 Pt 1):2535
   PubMed Web of Science ®Google Scholar
• Debrutne F, Gres AA, Arustamov DL. Placebo-controlled dose ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54(1):170
   PubMed Web of Science ®Google Scholar
• Striano P, Striano S. Gabapentin: a calcium channel alpha 2-delta ligand far beyond epilepsy therapy. Drugs Today (Barc) 2008;44(5):353
   PubMed Web of Science ®Google Scholar
• Carbone A, Palleschi G, Conte A, Gabapentin treatment of neurogenic overactive bladder. Clin Neuropharmacol 2006;29:206-14
   PubMed Web of Science ®Google Scholar
• Steers WD, Herschorn S, Kreder KJ, Duloxetine OAB study group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int 2007;100:337-45
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind placebo-controlled, randomized study. Br J Clin Pharmacol 2006;61:456-63
   PubMed Web of Science ®Google Scholar
• Mongin G. Tramadol extended release formulation in the management of pain due to osteoarthritis. Expert Rev Neurother 2007;7:1775-84
   PubMedGoogle Scholar
• Natalin R, Reis LO, Alpendre C, Tripple therapy in refractory detrusor overactivity: a preliminary study. World J Urol 2009. [Epub ahead of print]
   Google Scholar
• Ballet S, Aubel B, Mauborgne A, The novel analgesic, cizolirtine, inhibits the spinal release of substance P and CGRP in rats. Neuro Pharmacol 2001;40:578-89
   Google Scholar
• Aubel B, Kayser V, Mauborgne A, Evidence for adenosine and serotonin mediated antihyperalgesic effects of cizolirtine in rats suffering from diabetic neuropathy. Neuropharmacology 2007;52:487-96
   PubMed Web of Science ®Google Scholar
• Smet PJ, Moore KH, Jonavicius J. Distributin and colocalization of calcitonin gene-related peptide, tachykinins and vasoactive intestinal peptide in normal and idiopathic unstable urinary bladder. Lab Invest 1997;77:37-49
   PubMed Web of Science ®Google Scholar
• Zatura F, Vsetica J, Abadias M, Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. Eur Urol 2010;57:145-52
   PubMed Web of Science ®Google Scholar
• Chapple CR, Khullar V, Galmel Z, The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54(3):543-62
   PubMed Web of Science ®Google Scholar
• Hiragata S, Ogawa T, Hayashi Y, Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats. Urology 2007;70:202-8
   PubMed Web of Science ®Google Scholar